Law firms Pinsents and Linklaters act on latest big pharma deal as Teva sells Allergan generics business for £600m Legal Business · 6 October 2016 · 1 min read Corporate and M&A Deal watch Linklaters Pinsent Masons Pinsent Masons and Linklaters are advising on Teva Pharmaceutical Industries’ sale of UK and Ireland business Activas Generics for £603m as the Israeli firm seeks to divest assets following last year’s takeover of Allergan.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryLinklaters closes Hamburg office amid plans to refocus German operationsLaw firmsKate Peacock16 Apr 2026Five law firms win appointments on FCA’s ‘skilled person’ investigations panelLaw firmsTheresa Hargreaves13 Apr 2026Linklaters and Slaughters lead on £1.4bn takeover of FTSE 250 manufacturer SeniorLaw firmsWill Lewallen10 Apr 2026How CMS M&A partner David Roberts became the restaurant expert on both sides of the tableLaw firmsKate Peacock20 Apr 2026‘We’ve got the building blocks in place to grow’ – Harbottle closes in on £60mLaw firmsTom Cox17 Apr 2026Hogan Lovells and Cadwalader partners approve largest ever law firm mergerLaw firmsKate Peacock15 Apr 2026Dealwatch: Global 100 advisers take centre stage on BlackRock-GIP $12.5bn mega dealLaw firmsAlex Ryan15 Jan 2024Dealwatch: Telegraph auction off as Barclay brothers pay off Lloyds debt with loanLaw firmsAlex Ryan8 Dec 2023Deal Watch: activity powers on as Latham and A&O lead on $19bn energy joint ventureLaw firmsMegan Mayers9 Sep 2022